Newer prodrug of tenofovir — preferential cleavage by lymphocyte cathepsin A → higher intracellular tenofovir-DP with much lower plasma tenofovir vs TDF. Reduced renal + bone toxicity. Replaces TDF in modern combination ART regimens.
Half-Life & Elimination Curve (PO: 26m)
Plasma (PO)t½ Decay (26m)
0×t½0h100%(42.3 µg/L)
1×t½26m50%(21.2 µg/L)
2×t½52m25%(10.6 µg/L)
3×t½1.29h12.5%(5.29 µg/L)
4×t½1.72h6.3%(2.64 µg/L)
5×t½2.15h3.1%(1.32 µg/L)
Elimination t½26m (PO)
Rate Constant (ke)1.61 h⁻¹
Time to Peak (Tmax)23m
Est. Peak (Cmax)42.3 µg/L
Clearance (CL)129 L/h
97% Washout (5×t½)2.15h
Dosing Guidelines
Oral (PO): Typical 25 mg (Range: 10–25 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 25% · Volume of Distribution (Vd): 80 L · Absorption (ka): 4 h⁻¹ (t½ka ≈ 10m) [PMID 34703277]